Switzerland-based Asceneuron SA has appointed Abbas Hussain, a pharma industry executive, as chair of its board of directors. Mr Hussain has held senior positions at major pharma companies for over 20 years including at GlaxoSmithKline, where he was global president, pharmaceuticals and vaccines and president Europe and emerging markets, and at Eli Lilly, where his career included President, European Operations.
Most recently he was chief executive officer and strategic advisor at Vifor Pharma which was acquired by CSL Limited in 2022 for $11.7 billion. Mr Hussain’s appointment comes as Asceneuron looks to further advance its lead clinical OGA inhibitors into the next stage of development for treating neurodegenerative disorders including Alzheimer's and Parkinson's disease, as well as orphan tauopathies. Mr Hussain holds a bachelor of science in medicinal and pharmaceutical chemistry from Loughborough Institute of Technology, UK and is a graduate of the Stanford Executive Program at Stanford University, US.
Asceneuron SA announced the appointment on December 18, 2023.
Copyright 2024 Evernow Publishing Ltd.